Ralexar Therapeutics, Inc., headquartered in Malvern, Pennsylvania, is a privately held specialty pharmaceutical company founded in January of 2014.

The company is developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis.